AMGN Amgen Inc. - Common Stock

Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]

Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...

Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]

Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.

Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]

Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The […]

Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

And there could be more positive developments ahead.

Mesirow CEO Richard S. Price with 1 Horizon Way in Deerfield (Getty, Mesirow, Google Maps)An entity tied to Chicago financial services firm Mesirow bought the Amgen office complex in Deerfield in a sale-leaseback deal for $151 million. The deal for the property, which spans 660,000 square feet of office space in three buildings at 1 Horizon Way along I-294 in suburban Deerfield, is rare for a site of its 70-acre size, according to Crain’s. The suburbs still suffer from high vacancy rates and sha

In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.

At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Peptides are everywhere lately. Influencers inject them for muscle and recovery, and the Food and Drug Administration could soon allow these products to be sold by compounding pharmacies. While the marketing of these injections to biohackers and wellness consumers will keep generating debate, the peptide boom that matters to biotech investors belongs to a company most TikTokers have never heard of.

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Amgen (NASDAQ:AMGN).

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.

Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...

Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.

Key Stats for Amgen StockPrice change for Amgen stock in last 1 year: 43%$AMGN Stock Price as of Sep. 22: $41052-Week High: $447$AMGN Stock Price Target: $388What Happened?Amgen (AMGN) stock rose after the company shared positive Phase 3 trial results.

(Updates with index/price moves and comments from the first paragraph.) US equity indexes ended m

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.

Amgen (NasdaqGS:AMGN) reported positive Phase 3 trial results for dazodalibep in Sjögren's disease, targeting a major unmet autoimmune need. The company described dazodalibep as a potential first-in-class therapy, following successful outcomes in patients with Sjögren's disease. Amgen received an FDA label update for IMDELLTRA in extensive-stage small cell lung cancer, reducing recommended patient monitoring times. The dazodalibep Phase 3 success and IMDELLTRA monitoring change both reshape...

(Updates with index/price moves and company/geopolitical news from the first paragraph.) US equit

Stock Market Today: The Dow Jones index was firm on U.S.-Iran peace hopes Tuesday as oil prices and Treasury yields continue to fall.

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.

A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.

VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.

Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...

Stock Market Today: The Dow Jones index rallies Monday as oil prices and Treasury yields drop. Nvidia and Google stock climb.

AMD's AI infrastructure demand is broadening as EPYC CPUs and Instinct accelerators gain traction, while Helios ramps and multigigawatt commitments boost visibility.

Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.

Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...

In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.

Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.

AMD, Linde and Amgen highlight AI demand, contracted growth and drug launches, while supply, margin and pipeline risks remain key factors.

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.

Key Stats for Amgen StockCurrent Price: $375. 65Target Price (Mid): ~$495Street Target: ~$388Potential Total Return: ~32%Annualized IRR: ~6.

The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.